Progyny, Inc. (PGNY) Hits Fresh High: Is There Still Room to Run?

A strong stock as of late has been Progyny (PGNY). Shares have been marching higher, with the stock up 2.4% over the past month. The stock hit a new 52-week high of $27.76 in the previous session. Progyny has gained 56.3% since the start of the year compared to the 7.6% move for the Zacks Medical sector and the 6.9% return for the Zacks Medical Services industry.What's Driving the Outperformance?The stock has an impressive record of positive earnings surprises, as it hasn't missed our earnings consensus estimate in any of the last four quarters. In its last earnings report on November 6, 2025, Progyny reported EPS of $0.45 versus consensus estimate of $0.39 while it beat the consensus revenue estimate by 4.19%.For the current fiscal year, Progyny is expected to post earnings of $1.8 per share on $1.27 in revenues. This represents a 9.76% change in EPS on a 9.16% change in revenues. For the next fiscal year, the company is expected to earn $1.93 per share on $1.39 in revenues. This represents a year-over-year change of 7.22% and 9.24%, respectively.Valuation MetricsWhile Progyny has moved to its 52-week high over the past few weeks, investors need to be asking, what is next for the company? A key aspect of this question is taking a look at valuation metrics in order to determine if the company is due for a pullback from this level.On this front, we can look at the Zacks Style Scores, as these give investors a variety of ways to comb through stocks (beyond looking at the Zacks Rank of a security). The individual style scores for Value, Growth, Momentum and the combined VGM Score run from A through F. The idea behind the style scores is to help investors pick the most appropriate Zacks Rank stocks based on their individual investment style.Progyny has a Value Score of B. The stock's Growth and Momentum Scores are A and D, respectively, giving the company a VGM Score of B.In terms of its value breakdown, the stock currently trades at 15X current fiscal year EPS estimates, which is not in-line with the peer industry average of 15.6X. On a trailing cash flow basis, the stock currently trades at 78.1X versus its peer group's average of 11X. Additionally, the stock has a PEG ratio of 0.9. This isn't enough to put the company in the top echelon of all stocks we cover from a value perspective.Zacks RankWe also need to look at the Zacks Rank for the stock, as this is even more important than the company's VGM Score. Fortunately, Progyny currently has a Zacks Rank of #2 (Buy) thanks to rising earnings estimates.Since we recommend that investors select stocks carrying Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, it looks as if Progyny passes the test. Thus, it seems as though Progyny shares could still be poised for more gains ahead.How Does PGNY Stack Up to the Competition?Shares of PGNY have been soaring, and the company still appears to be a decent choice, but what about the rest of the industry? One industry peer that looks good is CareDx, Inc. (CDNA). CDNA has a Zacks Rank of #2 (Buy) and a Value Score of C, a Growth Score of A, and a Momentum Score of C.Earnings were strong last quarter. CareDx, Inc. beat our consensus estimate by 115.38%, and for the current fiscal year, CDNA is expected to post earnings of $0.77 per share on revenue of $374.08 million.Shares of CareDx, Inc. have gained 11.5% over the past month, and currently trade at a forward P/E of 29.01X and a P/CF of 14.72X.The Medical Services industry may rank in the bottom 66% of all the industries we have in our universe, but there still looks like there are some nice tailwinds for PGNY and CDNA, even beyond their own solid fundamental situation.Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Progyny, Inc. (PGNY): Free Stock Analysis Report CareDx, Inc. (CDNA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks